Also Known As:
- Chronic Myelogenous Leukaemia
- Chronic Granulocytic Leukaemia (CGL)
Why is RareCan interested in Chronic Myeloid Leukaemia?
RareCan is working to accelerate research into CML by making it easier for researchers to connect with people who have this and other rare forms of blood cancer. You can help us do this by becoming a RareCan member and sharing information with us about your diagnosis. We will then get in touch with you about any research opportunities that might be suitable for you.
RARECAN ALREADY HAS
What is Chronic Myeloid Leukaemia?
Chronic Myeloid Leukaemia is a rare cancer that affects the white blood cells. It is characterised by uncontrolled growth of myeloid cells in the bone marrow and their accumulation in the blood.
How rare is CML?
In the UK, less than 1,000 people are diagnosed with CML each year. It accounts for 8% of all Leukaemias in the UK.
Who does CML affect?
CML affects people of all ages but is less common in children. It is more common in men than it is in women.
If you have Chronic Myeloid Leukaemia/Chronic Myelogenous Leukaemia/Chronic Granulocytic Leukaemia (CGL) and are looking for support, we recommend the following websites:
Opportunities for Members with Chronic Myeloid Leukaemia
The RareCan BioResource
Donating your samples for medical research
Joining RareCan gives you the ability to donate your tissue samples to the BioResource for medical research. Please note that signing up to RareCan does not commit you to donating tissue and you can cancel your membership at any time. If you have Chronic Myeloid Leukaemia and would like to find out more, please click the button below.
I have a cancer diagnosis
If you have a cancer diagnosis or you are the parent of a child with a cancer diagnosis, please start here.
I'm a supporter
If you’re a friend or family member of someone with cancer, a nurse, an oncologist, an activist, a fundraiser or you’d simply like to help, please start here.
I'm a researcher
If you are interested in setting up a research project or clinical trial aimed at improving the care people affected by rare cancer receive please start here.